澳洲最高法院拒受理上訴 強生須就問題盆骨植入物向3女賠償近260萬澳元
《路透》報道,澳洲最高法院拒絕受理強生(JNJ.US)就澳洲聯邦法院有關旗下Ethicon提出的上訴。
澳洲聯邦法院法官2019年11月就一項集體訴訟作出裁定,指Ethicon在出售盆骨網片植入物前沒有適當測試,亦沒有向醫生及治療尿失禁或骨盆腔器官脫垂女性警告有關風險。強生的有關上訴在今年3月於澳洲聯邦法院被駁回。涉及該宗集體訴訟的3名原告將分別獲得127.6萬、55.6萬及75.7萬澳元的賠償。
牽頭集體訴訟的Shine Lawyers已於今年4月向澳洲聯邦法院入稟第二批集體訴訟,受害人於2017年7月以後被植入有關出現問題的植入物。Shine Lawyers及強生均表示,案件將回歸澳洲聯邦法院,以處理涉及逾1萬宗同類索償案件。有關案件爲澳洲有史以來最大宗產品責任索償案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.